KNSA'
s Net Margin % Range Over the Past 10 Years
Min: -409.72 Med: 5.21 Max: 83.28
Current: 9.69
KNSA's Net Margin % is ranked better than 62.76% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs KNSA: 9.69
Kiniksa Pharmaceuticals International (NAS:KNSA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Kiniksa Pharmaceuticals International Net Margin % Related Terms
Kiniksa Pharmaceuticals International Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International Net Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Net Margin % distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International (KNSA) has a Net Margin % of 10.54% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Kiniksa Pharmaceuticals International and its competitors. This is 102% above median its historical median of 5.21. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #356 out of 956 companies in the Drug Manufacturers industry, placing it in the top 37.2%.
Is Kiniksa Pharmaceuticals International's Net Margin % too high?
Kiniksa Pharmaceuticals International's current Net Margin % of 10.54% is 102% above median its 10-year median of 5.21. The Drug Manufacturers industry median Net Margin % is 5.56. Kiniksa Pharmaceuticals International's value of 10.54% is 89.6% above this industry median. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #356 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kiniksa Pharmaceuticals International has a GF Scoreâ„¢ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Net Margin % compare to AMRX and INDV?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #356 out of 956 companies for Net Margin %. This puts Kiniksa Pharmaceuticals International in the upper half of its industry. The industry median Net Margin % is 5.56. Kiniksa Pharmaceuticals International's value of 10.54% is 89.6% above this benchmark. While the company's 10-year median is 5.21 vs. the industry median of 5.56, Kiniksa Pharmaceuticals International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiniksa Pharmaceuticals International's current Net Margin % of 10.54% is 89.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Kiniksa Pharmaceuticals International and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current Net Margin % is 10.54%, which is 102% above median its own 10-year median of 5.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Modestly Overvalued. The stock's GF Value™ is $47.89, compared to a current price of $59.72 — trading 24.7% above its estimated fair value. The current Net Margin % is 10.54%, which is 102% above median its 10-year median of 5.21 and 89.6% above the Drug Manufacturers industry median of 5.56. Kiniksa Pharmaceuticals International's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Net Margin % is 10.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $59.72 is trading 24.7% above its estimated GF Value™ of $47.89.
GuruFocus considers Kiniksa Pharmaceuticals International to be Modestly Overvalued.
Key valuation signals for KNSA:
Net Margin %: 10.54% (102% above median its 10-year median of 5.21)
GF Value™: $47.89 vs. price of $59.72 (24.7% above fair value)
Industry Position: 89.6% above the Drug Manufacturers median (#356 of 956)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International Business Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
56GF Score
Get the complete analysis for KNSA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
